Your browser doesn't support javascript.
loading
Cinobufotalin powerfully reversed EBV-miR-BART22-induced cisplatin resistance via stimulating MAP2K4 to antagonize non-muscle myosin heavy chain IIA/glycogen synthase 3ß/ß-catenin signaling pathway.
Liu, Yiyi; Jiang, Qingping; Liu, Xiong; Lin, Xian; Tang, ZiBo; Liu, Chen; Zhou, Jin; Zhao, Mengyang; Li, Xin; Cheng, Zhao; Li, Libo; Xie, Yingying; Liu, Zhen; Fang, Weiyi.
Afiliação
  • Liu Y; Cancer Center, Integrated Hospital of Traditional Chinese Medicine, Southern Medical University, Guangzhou, China.
  • Jiang Q; Cancer Institute, School of Basic Medical Science, Southern Medical University, Guangzhou, China; Department of Pathology, Third Affiliated Hospital, Guangzhou Medical University, Guangzhou, China.
  • Liu X; Cancer Institute, School of Basic Medical Science, Southern Medical University, Guangzhou, China; Department of Otolaryngology, Head and Neck Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, People's Republic of China.
  • Lin X; Cancer Center, Integrated Hospital of Traditional Chinese Medicine, Southern Medical University, Guangzhou, China.
  • Tang Z; Cancer Center, Integrated Hospital of Traditional Chinese Medicine, Southern Medical University, Guangzhou, China.
  • Liu C; Cancer Center, Integrated Hospital of Traditional Chinese Medicine, Southern Medical University, Guangzhou, China.
  • Zhou J; Cancer Center, Integrated Hospital of Traditional Chinese Medicine, Southern Medical University, Guangzhou, China.
  • Zhao M; Cancer Center, Integrated Hospital of Traditional Chinese Medicine, Southern Medical University, Guangzhou, China.
  • Li X; Shenzhen Key Laboratory of Viral Oncology, the Clinical Innovation & Research Center (CIRC), Shenzhen Hospital, Southern Medical University, Shenzhen, China.
  • Cheng Z; Shenzhen Key Laboratory of Viral Oncology, the Clinical Innovation & Research Center (CIRC), Shenzhen Hospital, Southern Medical University, Shenzhen, China; Department of Pediatric Otorhinolaryngology, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
  • Li L; Cancer Center, Integrated Hospital of Traditional Chinese Medicine, Southern Medical University, Guangzhou, China.
  • Xie Y; Cancer Center, Integrated Hospital of Traditional Chinese Medicine, Southern Medical University, Guangzhou, China.
  • Liu Z; Cancer Center, Integrated Hospital of Traditional Chinese Medicine, Southern Medical University, Guangzhou, China; Key Laboratory of Protein Modification and Degradation, School of Basic Medical Sciences, Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou, China. Ele
  • Fang W; Cancer Center, Integrated Hospital of Traditional Chinese Medicine, Southern Medical University, Guangzhou, China. Electronic address: fangweiyi1975@163.com.
EBioMedicine ; 48: 386-404, 2019 Oct.
Article em En | MEDLINE | ID: mdl-31594754
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Bufanolídeos / RNA Viral / Cisplatino / Herpesvirus Humano 4 / Resistencia a Medicamentos Antineoplásicos / MicroRNAs Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: EBioMedicine Ano de publicação: 2019 Tipo de documento: Article País de afiliação: China País de publicação: Holanda
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Bufanolídeos / RNA Viral / Cisplatino / Herpesvirus Humano 4 / Resistencia a Medicamentos Antineoplásicos / MicroRNAs Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: EBioMedicine Ano de publicação: 2019 Tipo de documento: Article País de afiliação: China País de publicação: Holanda